Metoprolol tartrate controlled release tablets

This drug belongs to Class 2A, i.e., a α1-receptor blocker without partial agonist activity (cardioselective α1-receptor blocker). It has a selective blocking effect on α1-receptors, no PAA (partial agonist activity), and no membrane stabilizing effect. Its effect in blocking α1-receptors is approximately equal to that of propranolol (PP), and its selectivity for α1-receptors is slightly inferior to that of atenolol. Metoprolol's effects on the heart, such as slowing heart rate, inhibiting cardiac contractility, reducing automaticity, and delaying atrioventricular conduction time, are similar to those of propranolol and atenolol (AT). Its effect in reducing elevated blood pressure and heart rate during exercise testing is also similar to that of PP and AT. Its contraction effect on vascular and bronchial smooth muscle is weaker than that of PP, so its effect on the respiratory tract is also smaller, but still stronger than that of AT. Metoprolol can also reduce plasma renin activity.

Metoprolol tartrate.

This product is white or off-white tablets.

Hypertension, angina pectoris, etc.

Oral administration: 0.1 g per day, taken in the morning or as directed by a physician.

1. Cardiovascular system: slowed heart rate, conduction block, lowered blood pressure, worsening heart failure, cold limbs or untouchable pulse due to peripheral vascular spasm, Raynaud's disease. 2. Because of its fat solubility and easy penetration into the central nervous system, this system has more adverse reactions. Fatigue and dizziness account for 10%, depression accounts for 5%, and others include headache, dreaminess, insomnia, etc. Hallucinations are occasionally seen. 3. Digestive system: nausea, stomach pain, constipation <1%, diarrhea accounts for 5%, but it is not serious and rarely affects medication. 4. Others: shortness of breath, joint pain, itching, retroperitoneal fibrosis, deafness, eye pain, etc.

Significant bradycardia (heart rate 45/minute), cardiogenic shock, severe or acute heart failure, poor peripheral circulation perfusion, second-degree or third-degree atrioventricular block, sick sinus syndrome, and severe peripheral vascular disease.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not for use by pregnant women. Precautions for the elderly: Not yet clear.

Co-administration with cimetidine or prior use of quinidine may increase the blood concentration of metoprolol.

Store in a light-proof, sealed, dry place.

100mg

24 months

Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.

• Founded in:

  1993-01-28

• Address:

  No. 808, Binjiang East Road, Haizhu District, Guangzhou

• Tax NO.:

  91440101190485108B

• Registered Funds:

  45.693 million yuan

• Website:

  Log in to view

• Email:

  Log in to view